ACAD:NSD-ACADIA Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 18.54

Change

0.00 (0.00)%

Market Cap

USD 2.98B

Volume

1.12M

Avg Analyst Target

USD 26.63 (+43.61%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. Address: 12830 El Camino Real, San Diego, CA, United States, 92130

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD131.81B 38.58 31.39
BNTX BioNTech SE

N/A

USD67.50B 15.50 10.94
REGN Regeneron Pharmaceuticals Inc

N/A

USD61.22B 10.34 7.53
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD47.61B 24.20 15.87
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD35.36B N/A N/A
SGEN Seagen Inc

N/A

USD31.19B 53.49 43.63
GMAB Genmab A/S

N/A

USD30.55B 78.60 8.55
ALNY Alnylam Pharmaceuticals Inc

N/A

USD23.60B N/A N/A
RPRX Royalty Pharma plc

N/A

USD22.77B 30.36 12.47

ETFs Containing ACAD

Symbol Name Weight Mer Price(Change) Market Cap
CHEP AGFiQ U.S. Market Neutral.. 0.00 % 1.42 %

N/A

USD0.75M
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

N/A

USD1.96B
LABU Direxion Shares ETF Trust.. 0.00 % 1.02 %

N/A

USD0.77B
SIZ AGFiQ U.S. Market Neutral.. 0.00 % 2.82 %

N/A

USD0.88M
XBI SPDR S&P Biotech ETF 0.00 % 0.35 %

N/A

USD7.36B
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

N/A
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -65.32% 7% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.32% 7% F 4% F
Trailing 12 Months  
Capital Gain -57.05% 12% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.05% 12% F 5% F
Trailing 5 Years  
Capital Gain -21.47% 47% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.47% 47% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain 14.64% 51% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.64% 51% F 58% F
Risk Return Profile  
Volatility (Standard Deviation) 62.59% 49% F 28% F
Risk Adjusted Return 23.39% 50% F 38% F
Market Capitalization 2.98B 89% B+ 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.01 36% F 29% F
Price / Cash Flow Ratio -21.87 78% C+ 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -42.63% 66% D 31% F
Return on Invested Capital -43.31% 56% F 19% F
Return on Assets -17.75% 69% D+ 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.42 42% F 26% F
Short Percent 7.17% 34% F 25% F
Beta 0.66 80% B- 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.